---
title: "Rexulti (brexpiprazole), all indications: Drug interactions questions"
description: "Drug interactions questions on Rexulti (brexpiprazole) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Rexulti have? Which drugs can be taken with Rexulti without a dose adjustment? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/rexulti/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole), all indications: Drug interactions questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)

## Drug interactions

<a id="rexulti-drug-interactions"></a>

### What drug interactions does Rexulti have?

> “See Table 12 for clinically important drug interactions with REXULTI. 
> Table 12 
> Clinically Important Drug Interactions with REXULTI 
> Strong CYP3A4 Inhibitors 
> Clinical 
> Impact: 
> Concomitant use of REXULTI with strong CYP3A4 inhibitors increased the exposure of 
> brexpiprazole compared to the use of REXULTI alone [see Clinical Pharmacology (12.3)]. 
> Intervention: With concomitant use of REXULTI with a strong CYP3A4 inhibitor, reduce the REXULTI 
> dosage [see Dosage and Administration (2.7)]. 
> Strong CYP2D6 Inhibitors 
> Clinical 
> Impact: 
> Concomitant use of REXULTI with strong CYP2D6 inhibitors increased the exposure of 
> brexpiprazole compared to the use of REXULTI alone [see Clinical Pharmacology (12.3)]. 
> Intervention: With concomitant use of REXULTI with a strong CYP2D6 inhibitor, reduce the REXULTI 
> dosage [see Dosage and Administration (2.7)]. 
> Both CYP3A4 Inhibitors and CYP2D6 Inhibitors  
> Clinical 
> Impact: 
> Concomitant use of REXULTI with 1) a strong CYP3A4 inhibitor and a strong CYP2D6 
> inhibitor; or 2) a moderate CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 3) a strong 
> CYP3A4 inhibitor and a moderate CYP2D6 inhibitor; or 4) a moderate CYP3A4 inhibitor and a 
> moderate CYP2D6 inhibitor increased the exposure of brexpiprazole compared to the use of 
> REXULTI alone [see Clinical Pharmacology (12.3)]. 
> Intervention: 
> With concomitant use of REXULTI with 1) a strong CYP3A4 inhibitor and a strong CYP2D6 
> inhibitor; or 2) a moderate CYP3A4 inhibitor and a strong CYP2D6 inhibitor; or 3) a strong 
> CYP3A4 inhibitor and a moderate CYP2D6 inhibitor; or 4) a moderate CYP3A4 inhibitor and a 
> moderate CYP2D6 inhibitor, decrease the REXULTI dosage [see Dosage and Administration 
> (2.7)].”

Source: [REXULTI: Prescribing information, page 20, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=20)

> “Strong CYP3A4 Inducers  
> Clinical 
> Impact: 
> Concomitant use of REXULTI and a strong CYP3A4 inducer decreased the exposure of 
> brexpiprazole compared to the use of REXULTI alone [see Clinical Pharmacology (12.3)]. 
> Intervention: With concomitant use of REXULTI with a strong CYP3A4 inducer, increase the REXULTI 
> dosage [see Dosage and Administration (2.7)]. 
> *In the clinical studies examining the adjunctive use of REXULTI in the treatment of MDD, dosage was not adjusted for strong CYP2D6 
> inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations, and 
> REXULTI may be administered without dosage adjustment in patients with MDD.”

Source: [REXULTI: Prescribing information, page 21, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=21)

<a id="rexulti-no-interaction-drugs"></a>

### Which drugs can be taken with Rexulti without a dose adjustment?

> “Based on pharmacokinetic studies, no dosage adjustment of REXULTI is required when administered 
> concomitantly with CYP2B6 inhibitors (e.g., ticlopidine) or gastric pH modifiers (e.g., omeprazole). Additionally, 
> no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 
> (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered 
> concomitantly with REXULTI.”

Source: [REXULTI: Prescribing information, page 21, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=21)

## Related pages
- [Medical information: Rexulti (brexpiprazole): All indications](https://www.evicenter.com/medical-information/rexulti)
- [Indication](https://www.evicenter.com/medical-information/rexulti/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rexulti/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/rexulti/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/rexulti/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti/access-and-coverage)
